Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal

Vaccine

Volumn 33, Issue 39, 2015, Pages 5057-5063

  Gonçalves, Guilherme ^a,b   Frade, João ^c,d   Nunes, Carla ^d,e   Mesquita, João Rodrigo ^f   Nascimento, Maria São José ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b Multidisciplinary Unit for Biomedical Research UMIB   (Portugal)

^c POLYTECHNIC INSTITUTE OF LEIRIA   (Portugal)

^d UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^e Centro de Investigação em Saúde Pública ^*  (Portugal)

^f POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

Author keywords

Antibodies; Immunisation; Measles; Measles mumps rubella (MMR) vaccine; Vaccination schedule

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE ERADICATION; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; POPULATION; PORTUGAL; PRIORITY JOURNAL; TIME TO TREATMENT; VACCINE FAILURE; ADOLESCENT; BLOOD; COHORT ANALYSIS; IMMUNIZATION; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD; TIME FACTOR;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; PORTUGAL; TIME FACTORS;

EID: 84941739145     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.057     Document Type: Article

References (28)

1. Cutts F.T., Lessler J., Metcal C.J.E. Measles elimination progress: challenges and implication for rubella control. Expert Rev Vaccines 2013, 12(8):917-932.
2. Seward J.F., Orenstein W.A. A rare event: a measles outbreak in a population with 2-dose measles vaccine coverage. Clin Infect Dis 2012, 55(3):403-405.
3. Uzicanin A., Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis 2011, 204:S133-S148.
4. Paunio M., Peltola H., Valle M., Davidkin I., Virtanen M., Heinonen O.P. Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine. J Epidemiol Commmunity Health 1999, 53:173-178.
5. European Centre for Disease Prevention and Control (ECDC). Vaccine schedule. Recommended immunisations for measles. Stockholm: ECDC; 2005. Available at 〈http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx〉. [Accessed Dec 2014].
6. Moss W.J., Scott S. WHO immunological basis for immunization series. Module 9: measles 2009, World Health Organzation, Geneva, Switzerland.
7. LeBaron C.W., Beeler J., Sullivan J., Forghani B., Daoling Bi Beck C., Audet S., et al. Persistence of measles antibodies after 2 doses pf measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007, 161:294-3001.
8. Measles: reassessment of the current immunization policy. Pediatrics 1989, 84:1110-1113. American Academy of Pediatrics, Committee on Infectious Diseases.
9. CDC.Measles prevention Recommendations of the immunization practices advisory committee (ACIP). MMWR. Morb Mortal Wkly Rep 1989, 38(S-9):1-18.
10. CDC Measles, Mumps, and Rubella - Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morb Mortal Wkly Rep 1998, 47(RR-8):1-57.
11. Davidkin I., Jokinen S., Broman Mia Leinikki Peltola H. Peristence of measles, mumps and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. JID 2008, 197:950-956.
12. Poethko-Müller C., Mankertz A. Seroprevalence of measles-, mumps- and rubella- specific IgG antibodies in German children and adolescents and predictors of seronegativity. PLoS One 2012, 7(8):e42867.
13. Theeten H., Hutse V., Hens N., Yavuz Y., Hoppenbrouwers K., Beutles P., et al. Are we hitting immunity targets?: the 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium. Epidemiol Infect 2011, 139:494-504.
14. Vandermeunlen C., Roelants M., Leroux-Roels G., Van Damme P., Hoppenbrouwers K. Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 2007, 25:6672-6676.
15. CDC Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013. Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morb Mortal Wkly Rep 2013, 62:1-38.
16. Portugal. Ministério da Saúde. Direcção-Geral da Saúde Programa Nacional de Eliminação do Sarampo (NORMA Número:006/2013 Data: 02/04/2013) Available from: 〈http://www.dgs.pt/documentos-e-publicacoes/programa-nacional-de-eliminacao-do-sarampo.aspx〉. [Accessed Mar 2015].
17. Gonçalves G., Nascimento M.S.J., Réu C., Cutts F.T. Levels of rubella antibody among vaccinated and unvaccinated Portuguese mothers and their newborns. Vaccine 2006, 24:7142-7147.
18. Portugal. Direcção-Geral da Saúde Programa Nacional de Vacinação (Orientações Técnicas 10). Lisboa; 2001.
19. Portugal. Ministério da Saúde Direção Geral de Saúde. Programa nacional de vacinação: normas de vacinação. Lisboa: DGS, 2012. (Circular Normativa 04/2011 de 26/01/2012) Available from: 〈http://www.dgs.pt/pagina.aspx?f=1&lws=1&mcna=0&lnc=&mid=5005&codigoms=0&codigono=683368347177AAAAAAAAAAAA〉. [Accessed Mar 2015].
20. Gonçalves G. Eficácia vacinal durante a epidemia de sarampo de 1988 e 1989, no Porto e arredores. Arquivos de Medicina 1996, 10:22-27.
21. Gonçalves G., Frutuoso M.A., Ferreira M.C., Freitas M.G. High vaccine coverage in the North of Portugal. A strategy to assess and increase coverage. Eurosurveillance 2005, 10(4-6):98-102.
22. Portugal. Direcção-Geral da Saúde Avaliação do Programa Nacional de Vacinação. 2° Inquérito Serológico Nacional. Portugal Continental 2001-2002.-Lisboa 2004. [ISBN 972-675-101-2].
23. Dopatka H.D., Giesendorf B. Single point quantification of antibody by ELISA without need of a reference curve. J Clin Lab Anal 1992, 6:417-422.
24. Riddell M.A., Byrnes B.G., Leydon J.A., Kelly H.A. Dried venous blood samples for the detection and quantification of measles IgG using a commercial enzyme immnunoassay. Bull World Health Organ 2003, 81(10):701-707.
25. Kakoulidou M., Ingelman-Sundberg H., Johansson E., Cagigi A., Farouk S.E., Nilsson A., et al. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults. Vaccine 2013, 31:711-717.
26. Gonçalves G. Herd immunity: recent uses in vaccine assessment. Expert Rev Vaccines 2008, 7(10):1493-1506.
27. Wood J.G., Gidding H.F., Heywood A., Macartney K., McIntyre P.B., McIntyre C.R. Potentail impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia. Vaccine 2009, 27:313-318.
28. Viana P.O., Ono E., Miyamoto M., Salomao R., Costa-Carvalho B.T., Weckx L.Y., et al. Humoral and cellular responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen. J Clin Immunol 2010, 30:574-582.